Cover Image
市場調查報告書

胰臟炎:開發中產品分析

Pancreatitis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 246013
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
胰臟炎:開發中產品分析 Pancreatitis - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 74 Pages
簡介

胰臟炎是指胰臟發炎,症狀是上腹部痛、噁心、嘔吐、碰觸腹部會有壓痛,以及體重減輕等。發病的要因有酒精成癮、吸煙、胰臟炎的家族病史、感染症、腹部受傷及胰臟癌等。治療方法為抗生素及緩和痛覺用的藥物療法。

本報告提供胰臟炎治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

胰臟炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

胰臟炎:企業開發中的治療藥

胰臟炎:大學/機關研究中的治療藥

胰臟炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

胰臟炎:企業開發中的產品

胰臟炎:大學/機關研究中的產品

胰臟炎的治療藥開發企業

  • Angion Biomedica Corp.
  • Atox Bio Inc.
  • Bharat Serums And Vaccines Limited
  • CalciMedica, Inc.
  • Dynavax Technologies Corporation
  • Generon (Shanghai) Corporation Ltd.
  • GlaxoSmithKline Plc
  • Pharming Group N.V.

胰臟炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

胰臟炎:最近的開發平台趨勢

胰臟炎:暫停中的計劃

胰臟炎:中止開發的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9720IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides an overview of the Pancreatitis (Gastrointestinal) pipeline landscape.

Pancreatitis is an inflammation of pancreas. Symptoms include upper abdominal pain, nausea, vomiting, and tenderness when touching the abdomen, weight loss and upper abdominal pain. Predisposing factors include alcoholism, smoking, family history of pancreatitis, infection, injury to the abdomen and pancreatic cancer. Treatment includes antibiotics and medication to relieve pain.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pancreatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Pancreatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 1, 14 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Pancreatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Pancreatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pancreatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pancreatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pancreatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pancreatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pancreatitis - Overview
    • Pancreatitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pancreatitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pancreatitis - Companies Involved in Therapeutics Development
    • Angion Biomedica Corp
    • Bharat Serums And Vaccines Ltd
    • CalciMedica Inc
    • Cypralis Ltd
    • Dynavax Technologies Corp
    • Generon (Shanghai) Corp Ltd
    • GlaxoSmithKline Plc
    • LipimetiX Development Inc
    • Novartis AG
    • Pharming Group NV
    • Sarfez Pharmaceuticals Inc
    • Sun BioPharma Inc
    • Takeda Pharmaceutical Company Ltd
  • Pancreatitis - Drug Profiles
    • AAD-2004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AEM-2814 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ANG-3070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (recombinant) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-4620 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DV-1179 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-180 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2795039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-3335065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-428 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-6288B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-2pal18S - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptides to Agonize RNLS for Acute Pancreatitis, Acute Kidney Injury and Cisplatin Induced Kidney Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Inhibit CXCL for Pancreatitis, Cardiovascular and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Cyclophilin D for Acute Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KMO for Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Soluble Epoxide Hydrolase for Acute Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Trypsin for Pancreatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-20201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-671 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulinastatin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Withaferin A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pancreatitis - Dormant Projects
  • Pancreatitis - Discontinued Products
  • Pancreatitis - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2017: Sun BioPharma Provides Clinical Update
      • May 24, 2017: CalciMedica Receives Fast-Track Designation for CM4620, a Novel CRAC Channel Inhibitor to Treat Acute Pancreatitis
      • Feb 01, 2017: The NIH Awards Sun BioPharma Grant to Study SBP-101 for the Treatment of Pancreatitis
      • Jan 05, 2017: CalciMedica Initiates Phase 1 Clinical Studies for CRAC Channel Inhibitor
      • Oct 24, 2016: Sun BioPharma to Present at the Innovation Biotech Showcase on October 26th
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pancreatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pancreatitis - Pipeline by Angion Biomedica Corp, H2 2017
  • Pancreatitis - Pipeline by Bharat Serums And Vaccines Ltd, H2 2017
  • Pancreatitis - Pipeline by CalciMedica Inc, H2 2017
  • Pancreatitis - Pipeline by Cypralis Ltd, H2 2017
  • Pancreatitis - Pipeline by Dynavax Technologies Corp, H2 2017
  • Pancreatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2017
  • Pancreatitis - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Pancreatitis - Pipeline by LipimetiX Development Inc, H2 2017
  • Pancreatitis - Pipeline by Novartis AG, H2 2017
  • Pancreatitis - Pipeline by Pharming Group NV, H2 2017
  • Pancreatitis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017
  • Pancreatitis - Pipeline by Sun BioPharma Inc, H2 2017
  • Pancreatitis - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Pancreatitis - Dormant Projects, H2 2017
  • Pancreatitis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Pancreatitis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top